Photo credit: Agilent / CC0 public domain
At the American Diabetes Association’s most recent scientific meeting in 2021, researchers from Massachusetts General Hospital (MGH) were positive about testing the Calmette Guerlain (BCG) vaccine to safely and significantly lower blood sugar levels. We announced the latest information.
In type 1 diabetes, an autoimmune disease for which there is currently no cure, T cells attack the pancreas and destroy the ability of glucose to enter the cells and produce insulin, the hormone essential for energy production. .. In a previous study, Denise Faustman, MD, Ph.D., director of the MGH Institute for Immunobiology. They found that BCG boosts a substance called TNF, eliminates harmful T cells, and helps develop useful T cells called regulatory T cells. Or Treg.
Key findings include a new understanding of how responses to BCG vaccination vary with the age of onset of patients, and in addition to the role of BCG vaccination in altering glucose transport and altering Tregs. Including support. Currently, 143 patients with type 1 diabetes are receiving at least two doses of BCG, of which 25 will be enrolled in a recently initiated study in pediatric adults. In anticipation of FDA approval, MGH plans to begin a multi-center pediatric study this year.
“More data from randomized, double-blind clinical trials will be announced as we look at additional results from Phase II trials,” said Faustmann, lead investigator in MGH’s BCG clinical trials. Specified. “We continued to demonstrate BCG’s ability to reset and restore the immune system.”
In 2018, MGH announced the results of a follow-up phase I study in long-term diabetics treated with BCG with sustained clinical and statistically significant HbA1c levels followed up for 8 years. Showed a significant decrease. The new dates from ADA are:
Patients with type 1 diabetes who are younger than 21 years of age have faster reaction times and greater changes in HbA1c than patients with type 1 diabetes in adulthood.
Over a period of three years, BCG restored gene expression in Tregs in patients with type 1 diabetes to a pattern consistent with non-type 1 controls.
The 2-year HbA1c response in subjects with early onset of the disease is consistent with the 3-year response observed in phase 1 studies.
“BCG is an old vaccine, but it seems like a new gift,” said Nigel Curtis, MD, MD, Murdoch Children’s Research Institute in Melbourne, Australia. He has led global clinical studies on the beneficial and untargeted effects of the BCG vaccine, but was not involved in the current study. “This new data from MGH gives us a better understanding of how BCG changes the body’s response to autoimmune and infectious diseases.”
The BCG vaccination leads to a long-term improvement in blood sugar levels in patients with type 1 diabetes
Provided by
Massachusetts General Hospital
Quote: Https://medicalxpress.com/news/2021-06-bcg-vaccine-stemming-diabetes.html BCG for Type 1 Diabetes (June 25, 2021) Receive More Hope for Vaccines on June 25, 2021
This document is subject to copyright. No part may be reproduced without written permission except in fair transaction for personal investigation or research. The content is provided for informational purposes only.
More hope for BCG vaccine to curb type 1 diabetes Quellenlink Further hope for BCG vaccine to curb type 1 diabetes
